SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date
of
Report (date of earliest event reported): June
11, 2007.
BioTime,
Inc.
(Exact
name of registrant as specified in its charter)
|
California
|
1-12830
|
94-3127919
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
6121
Hollis Street
Emeryville,
California 94608
(Address
of principal executive offices)
(510)
350-2940
(Registrant's
telephone number, including area code)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Statements
made in this Report that are not historical facts may constitute forward-looking
statements that are subject to risks and uncertainties that could cause actual
results to differ materially from those discussed. Such risks and uncertainties
include but are not limited to those discussed in this report and in BioTime's
Annual Report on Form 10-K filed with the Securities and Exchange Commission.
Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” and similar expressions identify
forward-looking statements.
Section
7 - Regulation FD
Item 7.01
- Regulation FD Disclosure
The
press
release filed as Exhibit 99.1 is incorporated by reference.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated June 13, 2007
|
Section
9-Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated June 13, 2007
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
BIOTIME,
INC.
|
|
|
Date: June
13, 2007
|
By: /s/
Judith
Segall
|
|
Vice
President & Secretary
|
|
|
Member,
Office of the President
|
2
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Press
release dated June 13, 2007
|
3
Exhibit
99.1
BioTime,
Inc.
6121
Hollis Street
Emeryville,
CA 94608
Tel:
510-350-2940
Fax:
510-350-2948
www.biotimeinc.com
For
Further Information:
Judith
Segall (510) 350-2940
FOR
IMMEDIATE RELEASE
June
13,
2007
BIOTIME
TO SEEK NEW MARKETING PARTNERS FOR PENTALYTE®
EMERYVILLE,
CA, June 13, 2007 - BioTime,
Inc. (OTCBB: BTIM) announced today that Hospira, Inc. has declined an
opportunity to commercialize PentaLyte®
under
the terms offered by BioTime. PentaLyte®
is
BioTime’s proprietary pentastarch-based
plasma
volume expander in a balanced formulation. Hospira will continue to manufacture
and sell Hextend®
in the
United States under its License Agreement with BioTime and retains its right
to
obtain regulatory approval and market Hextend in Latin America and Australia.
BioTime already has licensing arrangements for PentaLyte®
in South
Korea, China and Taiwan, and a co-development agreement for
PentaLyte®
in
Japan. BioTime will offer other pharmaceutical companies the opportunity
to
license PentaLyte®
in the
remaining available territories.
About
BioTime, Inc.
BioTime,
headquartered in Emeryville, California, develops blood plasma volume expanders,
blood replacement solutions for hypothermic (low temperature) surgery, organ
preservation solutions and technology for use in surgery, emergency trauma
treatment and other applications. BioTime’s lead product Hextend is manufactured
and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ Corp.
under exclusive licensing agreements. Information about BioTime can be found
on
the web at www.biotimeinc.com.
Hextend®,
PentaLyte®,
and
HetaCool®
are
registered trademarks of BioTime, Inc.
Forward
Looking Statements
The
matters discussed in this press release include forward-looking statements
which
are subject to various risks, uncertainties and other factors that could
cause
actual results to differ materially from the results anticipated. Such risks
and
uncertainties include but are not limited to the results of clinical trials
of
BioTime products; the ability of BioTime and its licensees to obtain additional
FDA and foreign regulatory approval to market BioTime products; competition
from
products manufactured and sold or being developed by other companies; and
the
price of and demand for BioTime products. Other factors that could affect
BioTime’s operations and financial condition are discussed in BioTime’s Annual
Report on Form 10-KSB filed with the Securities and Exchange
Commission.